Literature DB >> 26622841

A single center clinical analysis of children with neuroblastoma.

Jing-Bo Shao1, Zheng-Hua Lu1, Wen-Yan Huang2, Zhi-Bao Lv3, Hui Jiang1.   

Abstract

In the present study, the cases of 59 children diagnosed with neuroblastoma (NB) were retrospectively analyzed to assess the association between the short-term efficacy of treatment and prognostic factors. In total, 59 patients with NB that were diagnosed between July 1, 2008 and June 30, 2013 at Shanghai Children's Hospital were enrolled in the present study. The follow-up was performed until December 31, 2013, and the data revealed that 43 patients (72.9%) achieved complete remission (CR) or partial remission (PR). The 3-year overall survival (OS) rate of patients with stage I, II, III, IV and IVs disease was 100, 100, 65.6, 34.8 and 85.7%, respectively (P=0.02). The 3-year OS and event-free survival rates were evidently increased in patients with favorable histology compared with the rates in the patients with unfavorable histology (P=0.046 and 0.030, respectively). Univariate statistical analysis revealed that the factors significantly associated with prognosis were patient age, tumor stage and risk group (P=0.004, 0.02 and 0.001, respectively). The present study identified that tumor stage, risk group and patient age are important prognostic factors for NB. An age of 18 months was also hypothesized to be the cut-off for the prognosis of patients.

Entities:  

Keywords:  children; efficacy; neuroblastoma; prognosis

Year:  2015        PMID: 26622841      PMCID: PMC4579968          DOI: 10.3892/ol.2015.3588

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

Authors:  Rani E George; Wendy B London; Susan L Cohn; John M Maris; Cynthia Kretschmar; Lisa Diller; Garrett M Brodeur; Robert P Castleberry; A Thomas Look
Journal:  J Clin Oncol       Date:  2005-08-22       Impact factor: 44.544

Review 2.  Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.

Authors:  R E George; S Variend; C Cullinane; S J Cotterill; A G McGuckin; C Ellershaw; J Lunec; A D Pearson
Journal:  Med Pediatr Oncol       Date:  2001-01

3.  A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly.

Authors:  Michael Weintraub; Elisha Waldman; Benjamin Koplewitz; Allan I Bloom; Eitan Gross; Arnold I Freeman; Shoshana Revel-Vilk
Journal:  Pediatr Blood Cancer       Date:  2011-05-16       Impact factor: 3.167

4.  Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups.

Authors:  Inge M Ambros; Jun-ichi Hata; Vijay V Joshi; Borghild Roald; Louis P Dehner; Heinz Tüchler; Ulrike Pötschger; Hiroyuki Shimada
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

Review 5.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

6.  Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.

Authors:  S Umehara; A Nakagawa; K K Matthay; J N Lukens; R C Seeger; D O Stram; R B Gerbing; H Shimada
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

Review 7.  The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives.

Authors:  Wendy B London; Luca Boni; Thorsten Simon; Frank Berthold; Clare Twist; Mary Lou Schmidt; Robert P Castleberry; Katherine K Matthay; Susan L Cohn; Bruno De Bernardi
Journal:  Cancer Lett       Date:  2005-10-18       Impact factor: 8.679

8.  Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

Authors:  Alberto Garaventa; Stefano Parodi; Bruno De Bernardi; Daniela Dau; Carla Manzitti; Massimo Conte; Fiorina Casale; Elisabetta Viscardi; Maurizio Bianchi; Paolo D'Angelo; Giulio Andrea Zanazzo; Roberto Luksch; Claudio Favre; Angela Tamburini; Riccardo Haupt
Journal:  Eur J Cancer       Date:  2009-07-16       Impact factor: 9.162

9.  Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization.

Authors:  Michael Weintraub; Allan I Bloom; Eitan Gross; Shoshana Revel-Vilk; Sarit Shahroor; Benjamin Z Koplewitz; Arnold I Freeman
Journal:  Pediatr Blood Cancer       Date:  2004-08       Impact factor: 3.167

Review 10.  Molecular biology of neuroblastoma.

Authors:  V Castel; E Grau; R Noguera; F Martínez
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

View more
  4 in total

1.  Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.

Authors:  Srinivasulu Yerukala Sathipati; Divya Sahu; Hsuan-Cheng Huang; Yenching Lin; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

2.  High-risk, Expression-Based Prognostic Long Noncoding RNA Signature in Neuroblastoma.

Authors:  Divya Sahu; Shinn-Ying Ho; Hsueh-Fen Juan; Hsuan-Cheng Huang
Journal:  JNCI Cancer Spectr       Date:  2018-06-01

3.  Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma.

Authors:  Xiaoliang Liu; Feng Liu; Haifeng Yu; Qiaoqian Zhang; Fubao Liu
Journal:  Int J Gen Med       Date:  2022-04-05

4.  Transcription factor activity of estrogen receptor α activation upon nonylphenol or bisphenol A treatment enhances the in vitro proliferation, invasion, and migration of neuroblastoma cells.

Authors:  Hongda Ma; Yao Yao; Changli Wang; Liyu Zhang; Long Cheng; Yiren Wang; Tao Wang; Erguang Liang; Hui Jia; Qinong Ye; Mingxiao Hou; Fan Feng
Journal:  Onco Targets Ther       Date:  2016-06-13       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.